Urologic Complications in Patients with Diabetes

  • Stephania Casco
  • Jose Carlos Arroyo-Kuribreña
  • Elena Soto-VegaEmail author


Diabetes mellitus (DM) is a group of metabolic diseases associated with high glucose levels that cause systemic long-term damage, dysfunction, and failure of several tissues [2]. Among the consequences of this chronic hyperglycemic state, patients with DM suffer several urologic complications that involve endothelial and neural damage all along the genitourinary tract with significant economical and quality of life costs.


Urologic complications Bladder dysfunction Diabetic cystopathy Benign prostatic hyperplasia Urethral obstruction Erectile dysfunction Urinary tract infection 


  1. 1.
    Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel b3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165–73.PubMedCrossRefGoogle Scholar
  2. 2.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(1):S62–9.PubMedCentralCrossRefGoogle Scholar
  3. 3.
    Antonini G, Busetto GM, De Berardinis E, Giovannone R, Vicini P, Del Giudice F, Perito PE. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. Int J Impot Res. 2016;28(1):4–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Balhara YPS, Sarkar S, Gupta R. Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab. 2015;19(4):451.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Bjerggaard M, Charles M, Kristensen E, Lauritzen T, Sandbæk A, Giraldi A. Prevalence of sexual concerns and sexual dysfunction among sexually active and inactive men and women with screen-detected type 2 diabetes. Sex Med. 2015;3(4):302–10.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Berger P, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer A, Bartsch G, Frauscher F. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia. 2005;48:784–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Beshay E, Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model. Urology. 2004;64:1062.PubMedCrossRefGoogle Scholar
  8. 8.
    Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic- associated erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44:1296–301.PubMedCrossRefGoogle Scholar
  10. 10.
    Boyko EJ, Fihn SD, Scholes D, Chen CL, Normand EH, Yarbro P. Diabetes and the risk of acute urinary tract infection among postmenopausal women. Diabetes Care. 2002;25:1778–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown JS, Nyberg LM, Kusek JW, Diokno AC, Foldspang FNH, Herzog AR, Hunskarr S, Milsom I, Nygaard I, Subak LL, Thom DH. Proceedings of the National Institute of Diabetes and Digestive and Kidney Diseases International Symposium on epidemiologic issues in urinary incontinence in women. Am J Obstet Gynecol. 2003;188:S77–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Brown JS, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y. Incontinence in women with impaired glucose tolerance: results of the diabetes prevention program. J Urol. 2004;171:325–6.CrossRefGoogle Scholar
  13. 13.
    Canda AE, Dogan H, Kandemir O, Atmaca AF, Akbulut Z, Balbay MD. Does diabetes affect the distribution and number of interstitial cells and neuronal tissue in the ureter, bladder, prostate, and urethra of humans? Cent European J Urol. 2014;67(4):366.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Caqueiro J, Casqueiro J, ALves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(Suppl1):S27–36.Google Scholar
  15. 15.
    Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int. 2001;87:402–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Changolkar AK, Hypolite JA, Disanto M, Oates PJ, Wein AJ, Chacko S. Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol. 2005;173:309–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Chapple C, Nitti V, Khullar V, Wyndaele J, Herschom S, Van Kerrebroeck P, Beth M, Siddiqui E. Onset of action of the b3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;
  18. 18.
    Chen KC, Sung SY, Lin YT, Hsieh CL, Shen KH, Peng CC, Peng RY. Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise—evidences revealed by the rat model. BMC Urol. 2015a;15(1):113.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Chen Z, Miao L, Gao X, Wang G, Xu Y. Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med. 2015b;8(7):11289.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Cheng JT, Yu BC, Tong YC. Changes of M3-muscarinic receptor protein and mRNA expressions in the bladder urothelium and muscle layer of streptozotocin induced diabetic rats. Neurosci Lett. 2007;423:1–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009;49(4):491–7.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol. 2009;182:S18–26.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379–95. v.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Deli G, Bonsbyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. Neuroendocrinology. 2013;98(4):267–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Doruk H, Akbay E, Çayan S, Akbay E, Bozlu M, Acar D. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl. 2005;51(1):1–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012;
  28. 28.
    Enzlin P, Mathieu C, Van den Bruel A, Bosteels J, Vanderschueren D, Demyttenaere K. Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care. 2002;25:672–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114(1):23–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, Adesky MC, Clark AR, Roehrborn CG. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol. 1998;160:2041–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Maggi M. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000a;23:1737–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Geerlings SE, Stolk RP, Camps MJ, Netten PM, Hoekstra JB, Bouter PK, Braveboer B, Collet TJ, Jansz AR, Hoepelman AM. Asymptomatic bacteriuria can be considered a diabetic complication in women with diabetes mellitus. Adv Exp Med Biol. 2000b;485:309–14.PubMedCrossRefGoogle Scholar
  34. 34.
    Golbidi S, Laher I. Bladder dysfunction in diabetes mellitus. Front Pharmacol. 2010;1:136.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, Day WW. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. In: Mayo Clinic Proceedings (Vol. 87, No. 9). Elsevier; 2012. p. 843–852Google Scholar
  36. 36.
    Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou J, Tenke P, Wagenlehner F. Guidelines on urological infections. Eur Assoc Urol. 2009:1–108.
  37. 37.
    Grant P, Jackson G, Baig I, Quin J. Erectile dysfunction in general medicine. Clin Med. 2013;13(2):136–40.CrossRefGoogle Scholar
  38. 38.
    Gray MA, Wang CC, Sacks MS, Yoshimura N, Chancellor M, Nagatomi J. Time dependent alterations of select genes in streptozotocin-induced diabetic rat bladder. Urology. 2008;71:1214–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Grigoryan L, Zoorob R, Wang H, Trautner BW. Low concordance with guidelines for treatment of acute cystitis in primary care. In: Open forum infectious diseases (Vol. 2, No. 4). United States, Oxford University Press; 2015. p. ofv159.Google Scholar
  40. 40.
    Hamdan HZ, Kubbara E, Adam AM, Hassan OS, Suliman SO, Adam I. Urinary tract infections and antimicrobial sensitivity among diabetic patients at Khartoum, Sudan. Ann Clin Microbiol Antimicrob. 2015;14(1):1.CrossRefGoogle Scholar
  41. 41.
    He LY, Zhang YC, He JL, Li LX, Wang Y, Tang J, et al. The effect of immediate surgical bipolar plasmakinetic transurethral resection of the prostate on prostatic hyperplasia with acute urinary retention. Asian J Androl. 2016;18(1):134.PubMedCrossRefGoogle Scholar
  42. 42.
    Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13:317–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. PT. 2013;38(7):407:414–419.Google Scholar
  44. 44.
    Ikeda K, Wada Y, Foster HE, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol. 2000;164(1):180–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Jackson RA, Vittinghoff E, Kanaya AM, Resnick HE, Kritchevsky S, Miles T, Simonsick E, Brown JS. Aging and body composition. Obstet Gynecol. 2004;104:301–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Karoli R, Bhat S, Fatima J, Priya S. A study of bladder dysfunction in women with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2014;18(4):552.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kebapci N, Yenilmez A, Efe B, Entok E, Demirustu C. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn. 2007;26(6):814–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Latini DM, Penson DF, Lubeck DP, Wallace KL, Henning JM, Lue TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction study. J Urol. 2003;169:1437–42.PubMedCrossRefGoogle Scholar
  49. 49.
    Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am. 2001;28:335–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem Biophys. 2007;48(2–3):115–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Liu G, Daneshgari F. Temporal diabetes- and diuresis-induced remodeling of the urinary bladder in the rat. Am J Physiol Regul Integr Comp Physiol. 2006;291:R837.PubMedCrossRefGoogle Scholar
  52. 52.
    Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J. 2014;127(7):1357.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Malavige LS, Wijesekara P, Ranasinghe P, Levy JC. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. Eur J Med Res. 2015;20(1):1–7.CrossRefGoogle Scholar
  54. 54.
    Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006;176(4):1299–306.PubMedCrossRefGoogle Scholar
  55. 55.
    McVary KT, Rathnau CH, McKenna KE. Sexual dysfunction in the diabetic BB/WOR rat: a role of central neuropathy. Am J Phys. 1997;272:R259–67.Google Scholar
  56. 56.
    Mcvary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Updateon AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.PubMedCrossRefGoogle Scholar
  57. 57.
    Mobley D, Baum N. The obesity epidemic and its impact on urologic care. Rev Urol. 2015;17(3):165.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Morano S. Pathophysiology of diabetic sexual dysfunction. J Endocrinol Invest. 2003;26(3 Suppl):65–9.PubMedGoogle Scholar
  59. 59.
    Neves D. Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction. Free Radic Res. 2013;47(Suppl 1):49–69.PubMedCrossRefGoogle Scholar
  60. 60.
    Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Owiredu WK, Amidu N, Alidu H, Sarpong C, Gyasi-Sarpong CK. Determinants of sexual dysfunction among clinically diagnosed diabetic patients. Reprod Biol Endocrinol. 2011;9:70.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol. 2001;40:398–402.PubMedCrossRefGoogle Scholar
  63. 63.
    Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113:14–9.CrossRefGoogle Scholar
  64. 64.
    Rull JA, Aguilar-Salinas CA, Rojas R, Rios-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res. 2005;36(3):188–96.PubMedCrossRefGoogle Scholar
  65. 65.
    Satriano J. Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. Amino Acids. 2007;33:331–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50(6):1016–26.PubMedCrossRefGoogle Scholar
  67. 67.
    Sewify M, Nair S, Warsame S, Murad M, Alhubail A, Behbehani K, Tiss A. Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled Glycemia in Kuwait. J Diabetes Res. 2016;2016:6573215.PubMedCrossRefGoogle Scholar
  68. 68.
    Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S. Inflammatory signaling involved in high-fat diet induced prostate diseases. J Urol Res. 2015;2:1–16.Google Scholar
  69. 69.
    Shimizu S, Tsounapi P, Shimizu T, Honda M, Inoue K, Dimitriadis F, Saito M. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction? Int J Urol. 2014;21(9):856–64.PubMedCrossRefGoogle Scholar
  70. 70.
    Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113(suppl 1A):80S–4S.PubMedCrossRefGoogle Scholar
  71. 71.
    Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C, Guay A. Erectile dysfunction-an observable marker of diabetes mellitus? A large national epidemiological study. J Urol. 2007;117(4):1588.Google Scholar
  72. 72.
    Torimoto K, Fraser MO, Hirao Y, De Groat WC, Chancellor MB, Yoshimura N. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959–64.PubMedCrossRefGoogle Scholar
  73. 73.
    Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5(10):2503–12.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate. 2010;70(1):79–89.PubMedCrossRefGoogle Scholar
  75. 75.
    Wei-Chia L. The impact of diabetes on the lower urinary tract dysfunction. JTUA. 2009;20:155–61.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Stephania Casco
    • 1
  • Jose Carlos Arroyo-Kuribreña
    • 2
  • Elena Soto-Vega
    • 1
    • 3
    Email author
  1. 1.Departamento de Ciencias de la SaludUniversidad Popular Autónoma del Estado de PueblaPueblaMexico
  2. 2.Hospital Ángeles de PueblaPueblaMexico
  3. 3.Centro de Investigación Oncológica, Una Nueva Esperanza- UPAEPPueblaMexico

Personalised recommendations